Date: 2014-02-02
Type of information: Commercialisation agreement
Compound: ConfirmMDx for Prostate Cancer
Company: MDxHealth (Belgium) Prime Health Services (USA)
Therapeutic area: Diagnostic - Cancer - Oncology
Type agreement: commercialisation
Action mechanism: ConfirmMDx for Prostate Cancer is an epigenetic assay to help distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule in high risk patients who may require repeat biopsies and potential treatment. The test is able to detect an epigenetic field effect or \"halo\" associated with the cancerization process at the DNA level in cells adjacent to cancer foci. This molecular \"halo\" around a cancer lesion can be present despite having a normal appearance under the microscope.
Disease: prostate cancer
Details: * On February 20, 2014, MDxHealth, a molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, has announced that it has signed an agreement with Prime Health Services, Inc. (\"Prime Health\") a Preferred Provider Organization (PPO) network. This agreement covers all 50 states, offering patients greater access to MDxHealth\'s ConfirmMDx® for Prostate Cancer test. This agreement extends ConfirmMDx for Prostate Cancer testing to approximately 144 million covered lives throughout the U.S.
Financial terms:
Latest news:
